Volgen
Thomas Faunce
Titel
Geciteerd door
Geciteerd door
Jaar
Artificial photosynthesis as a frontier technology for energy sustainability
T Faunce, S Styring, MR Wasielewski, GW Brudvig, AW Rutherford, ...
Energy & Environmental Science 6 (4), 1074-1076, 2013
3412013
Energy and environment policy case for a global project on artificial photosynthesis
T Faunce
Energy & Environmental Science 6 (3), 695-698, 2013
3172013
Uniform format for disclosure of competing interests in ICMJE journals
JM Drazen, MB Van Der Weyden, P Sahni, J Rosenberg, A Marusic, ...
The Lancet 374 (9699), 1395-1396, 2009
2432009
Nanosilver and global public health: international regulatory issues
T Faunce, A Watal
Nanomedicine 5 (4), 617-632, 2010
1662010
Will international human rights subsume medical ethics? Intersections in the UNESCO Universal Bioethics Declaration
TA Faunce
Journal of medical ethics 31 (3), 173-178, 2005
1152005
Practical virtue ethics: healthcare whistleblowing and portable digital technology
S Bolsin, T Faunce, J Oakley
Journal of medical ethics 31 (10), 612-618, 2005
1022005
Three Australian whistleblowing sagas: lessons for internal and external regulation
TA Faunce, SNC Bolsin
Medical Journal of Australia 181 (1), 44-47, 2004
1012004
Decision-analytical modelling in health-care economic evaluations
X Sun, T Faunce
The European Journal of Health Economics 9, 313-323, 2008
1002008
Australian law dictionary
L Abbott, J Anderson, DK Anton, K Baker, J Barnes, G Barton, TG Beale, ...
Oxford University Press, 2010
862010
Supporting whistleblowers in academic medicine: training and respecting the courage of professional conscience
T Faunce, S Bolsin, WP Chan
Journal of Medical Ethics 30 (1), 40-43, 2004
852004
Sunscreen safety: the precautionary principle, the Australian therapeutic goods administration and nanoparticles in sunscreens
T Faunce, K Murray, H Nasu, D Bowman
NanoEthics 2, 231-240, 2008
782008
Integrated research into the nanoparticle–protein corona: a new focus for safe, sustainable and equitable development of nanomedicines
TA Faunce, J White, KI Matthaei
Future Medicine Ltd 3 (6), 859-866, 2008
672008
'Linkage'pharmaceutical evergreening in Canada and Australia
TA Faunce, J Lexchin
Australia and New Zealand Health Policy 4, 1-11, 2007
632007
On-grid batteries for large-scale energy storage: Challenges and opportunities for policy and technology
TA Faunce, J Prest, D Su, SJ Hearne, F Iacopi
MRS Energy & Sustainability 5, E11, 2018
592018
Developing and teaching the virtue-ethics foundations of healthcare whistle blowing
T Faunce
Monash Bioethics Review 23 (4), 41-55, 2004
472004
Pharmaceuticals, intellectual property and free trade: the case of the US–Australia Free Trade Agreement
P Drahos, B Lokuge, T Faunce, M Goddard, D Henry
Prometheus 22 (3), 243-257, 2004
462004
Will the Australia-United States free trade agreement undermine the pharmaceutical benefits scheme?
K Harvey, B Lokuge, P Drahos, T Faunce
Australasian Medical Association, 2004
452004
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy
T Faunce, E Doran, D Henry, P Drahos, A Searles, B Pekarsky, W Neville
Globalization and Health 1, 1-10, 2005
432005
Toxicological and public good considerations for the regulation of nanomaterial-containing medical products
TA Faunce
Expert Opinion on Drug Safety 7 (2), 103-106, 2008
422008
Whistleblowing and scientific misconduct: Renewing legal and virtue ethics foundations
TA Faunce, S Jefferys
Med. & L. 26, 567, 2007
412007
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20